Substituted melanocortin receptor-specific piperazine compounds
US7709484B1 · kind B1 · utility
4Cited by
90References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 19, 2005 |
| Grant date | May 4, 2010 |
| Priority date | — |
| Expiry date | Dec 4, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A substituted piperazine compound having the structure I:or the structure IX:or an enantomeric, stereoisomeric or diastereomeric form of the foregoing, and pharmaceutically acceptable salts thereof, where J, L, Q, W, A, R6, R7, z and y are as defined in the specification, and the carbon atoms marked with an asterisk can have any stereochemical configuration, which compounds bind to one or more melanocortin receptors and may be employed in pharmaceutical preparations for treatment of one or more melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.